Results 61 to 70 of about 86,503 (159)
Pharmacological approaches to ameliorate vincristine neuropathy [PDF]
, 2001 Vincristine has been an important agent in the treatment of especially pediatric malignancies for four decades. The dose-limiting side effect of vincristine is peripheral neuropathy resulting in pain, constipation, paresthesisas, and impaired motor ...
Gidding, Cornelia Elisabeth Maria +1 more
core +1 more source
Mechanical allodynia occurred in vincristine treated rats.
, 2014 With regard to (A) body weight and (B) motor function, there was no difference between Vincristine group and Sham group. (C) Compared to Sham group, the paw withdrawal threshold of Vincristine group was significantly decreased. (D) No significant changes
Guo-An Lin (526693) +10 more
core +1 more source
Bioavailability of cyclosphosphamide and vincristine after intraperitoneal administration in cats [PDF]
, 2014 Cyclophosphamide and vincristine are widely used intravenous chemotherapeutic agents in both human and veterinary oncology. Although intravenous administration of these chemotherapeutics is the gold standard in most treatment protocols, this route of ...
Voorhorst, M.J. +3 more
core +2 more sources
Frontiers in Neuroscience, 2019 Vincristine is an antineoplastic substance that is part of many chemotherapy regimens, used especially for the treatment of a variety of pediatric cancers including leukemias and brain tumors.
H. Starobova +6 more
doaj +1 more source
Mechanical allodynia occurred in vincristine treated rats.
, 2013 With regard to (A) body weight, (B) motor function and plasma levels of (C) aspartate aminotransferase and (D) alanine aminotransferase, there was no difference between Sham group and Vincristine group.
Le Niu (400722) +11 more
core +1 more source
Vincristine delays gastric emptying and gastrointestinal transit of liquid in awake rats
Brazilian Journal of Medical and Biological Research, 2009 We evaluated the effects of vincristine on the gastrointestinal (GI) motility of awake rats and correlated them with the course of vincristine-induced peripheral neuropathy.
A.A. Peixoto Júnior +7 more
doaj +1 more source
Severe Vincristine-Induced Peripheral Neuropathic Weakness in Both Lower Limbs in an Asian Adolescent with CYP3A4 rs2740574 TT Genotype [PDF]
Dongdong Zhang,1 Jie Bai2 1Department of Oncology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, People’s Republic of China; 2Department of Neurology, Xiangyang No.
Zhang D, Bai J
core
Vincristine: Can its therapeutic index be enhanced?
, 2009 Vincristine is one of the most widely used and more effective drugs in paediatric oncology. The dose-limiting toxicity of neuropathy, lack of proven neuroprotective measures and an incomplete understanding of the pharmacokinetics and pharmacogenetics of ...
Moore, Andrew +3 more
core +1 more source
EXPERIENCE WITH VINCRISTINE - ASSOCIATEC NEUROTOXICITY
, 2011 Objectives: To evaluate the frequency and severity of occurrence of vincristine-associatedneurotoxicity .Design: A retrospective case series studySetting: Hurlingham Oncology Clinic, Nairobi.Subjects: Thirty-eight patients treated for various neoplasms ...
OTHIENO-ABINYA, N.A., NYABOLA, L.O.
core
Phase I Study of Liposomal Vincristine
, 1999 PURPOSE: A phase I study of vincristine encapsulated inside 120-nm-diameter distearoylphosphatidylcholine-cholesterol liposomes was performed. The primary objectives were to determine the maximum-tolerated dose (MTD), recommended phase II dose, toxicity,
L. D. Mayer +12 more
core +1 more source